[倍氯米松对支气管哮喘患者的疗效评估]
[An evaluation of the efficacy of Beclometh in bronchial asthma patients].
作者信息
Molostova T N, Zubkov M N, Pankratov V S, Vlasenko S Iu
出版信息
Ter Arkh. 1992;64(3):64-6.
PMID:1440281
Abstract
Fifteen bronchial asthma patients were followed-up for 6 months. They were administered beclomet-250 in a daily dose 1000 micrograms. The patients' clinical status was characterized by positive changes, ventilation function of the lungs improved. The drug was discovered to produce no suppressive action on adrenal function. Besides, the patients did not develop oropharyngeal candidiasis.
摘要
对15例支气管哮喘患者进行了6个月的随访。他们每日服用倍氯米松250，剂量为1000微克。患者的临床状况呈现出积极变化，肺通气功能得到改善。发现该药物对肾上腺功能无抑制作用。此外，患者未发生口咽念珠菌病。
Zotero 插件